Nektar Therapeutics
NKTRNektar Therapeutics (NKTR) is a biotechnology company focused on developing innovative immuno-oncology, pain, and inflammatory treatments. It leverages its proprietary drug discovery platform to create therapies that stimulate the body's immune system to fight diseases, particularly cancer. The company collaborates with other pharmaceutical firms and seeks to bring novel therapies to market through its research and development efforts.
Company News
Prosight Management increased its stake in Nektar Therapeutics by 180,367 shares ($10.27 million) in Q1 2026, making it the fund's largest position at 8.67% of AUM. The biotech company's stock has surged nearly 600% over the past year as it prepares to launch Phase 3 trials for rezpegaldesleukin, its experimental autoimmune disease treatment. Wit...
A class action lawsuit has been filed against Nektar Therapeutics alleging that company defendants made materially false and misleading statements regarding the REZOLVE-AA trial. The complaint claims that enrollment in the trial did not follow applicable protocol standards, which likely had a significant negative impact on trial results and overa...
Nektar Therapeutics faces a securities class action lawsuit alleging the company misrepresented enrollment standards in its REZOLVE-AA Phase 2b clinical trial. Four patients with major eligibility violations were included in the trial, including two with unstable alopecia areata diagnosed less than six months prior and two who began treatment bef...
A class action lawsuit has been filed against Nektar Therapeutics for allegedly making false statements about its REZOLVE-AA trial. The company failed to disclose that trial enrollment did not follow protocol standards, and four ineligible patients were included. When Nektar announced the trial's failure to reach statistical significance on Decem...
A securities class action lawsuit has been filed against Nektar Therapeutics for allegedly making false and misleading statements regarding the REZOLVE-AA trial. The lawsuit claims the company failed to disclose that enrollment in the trial did not follow applicable instructions and protocol standards, which negatively impacted trial results and ...
